INDV vs. RNA, RYTM, TGTX, VERA, PTCT, CORT, MOR, DYN, MLTX, and ARVN
Should you be buying Indivior stock or one of its competitors? The main competitors of Indivior include Avidity Biosciences (RNA), Rhythm Pharmaceuticals (RYTM), TG Therapeutics (TGTX), Vera Therapeutics (VERA), PTC Therapeutics (PTCT), Corcept Therapeutics (CORT), MorphoSys (MOR), Dyne Therapeutics (DYN), MoonLake Immunotherapeutics (MLTX), and Arvinas (ARVN). These companies are all part of the "pharmaceutical preparations" industry.
Indivior (NASDAQ:INDV) and Avidity Biosciences (NASDAQ:RNA) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, community ranking, risk and valuation.
Indivior currently has a consensus target price of $36.00, suggesting a potential upside of 103.05%. Avidity Biosciences has a consensus target price of $38.29, suggesting a potential upside of 47.48%. Given Indivior's higher probable upside, research analysts plainly believe Indivior is more favorable than Avidity Biosciences.
Avidity Biosciences received 135 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 64.62% of users gave Avidity Biosciences an outperform vote.
In the previous week, Avidity Biosciences had 19 more articles in the media than Indivior. MarketBeat recorded 20 mentions for Avidity Biosciences and 1 mentions for Indivior. Indivior's average media sentiment score of 1.81 beat Avidity Biosciences' score of 0.61 indicating that Indivior is being referred to more favorably in the media.
Indivior has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.
Indivior has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
Indivior has a net margin of 0.44% compared to Avidity Biosciences' net margin of -2,103.78%. Indivior's return on equity of 842.72% beat Avidity Biosciences' return on equity.
60.3% of Indivior shares are held by institutional investors. 2.0% of Avidity Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Indivior beats Avidity Biosciences on 11 of the 17 factors compared between the two stocks.
Get Indivior News Delivered to You Automatically
Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Indivior Competitors List
Related Companies and Tools
